Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News
In This Article:
Halozyme Therapeutics shares tumbled Tuesday on a new Medicare approach to price negotiations for drugs that use additive products.
Oops, something went wrong
Halozyme Therapeutics shares tumbled Tuesday on a new Medicare approach to price negotiations for drugs that use additive products.